Moderna Expects Flu Vaccine Trial to Continue, Despite Missing Early Success Criteria

Moderna said an independent board recommended its flu vaccine trial continue, though early success criteria weren't met.
Moderna's shares fell over 3% on the news, though the company still expects to launch six vaccines in coming years.
The potential flu vaccine didn't produce enough cases among recipients compared to those given a different vaccine.
Moderna remains focused on non-COVID vaccines as sales of its coronavirus shot have declined.
The company anticipates seeking approval of an RSV vaccine this quarter and major vaccine launches over the next several years.